Cipla's Advair generic hits Europe; eyes Breo version?
This article was originally published in Scrip
Executive Summary
Cipla has launched a "cost-efficient" generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), in Germany and Sweden.
You may also be interested in...
Christmas Cheer For Cipla’s Seretide Equivalent In The UK
Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.
Christmas Cheer For Cipla’s Seretide Equivalent In The UK
Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.